PT  - JOURNAL ARTICLE
AU  - Pinker, Katja
AU  - Riedl, Christopher C.
AU  - Ong, Leonard
AU  - Jochelson, Maxine
AU  - Ulaner, Gary A.
AU  - McArthur, Heather
AU  - Dickler, Maura
AU  - Gönen, Mithad
AU  - Weber, Wolfgang A.
TI  - The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by <sup>18</sup>F-FDG PET/CT Using PERCIST
AID  - 10.2967/jnumed.115.166629
DP  - 2016 Jul 01
TA  - Journal of Nuclear Medicine
PG  - 1102--1104
VI  - 57
IP  - 7
4099  - http://jnm.snmjournals.org/content/57/7/1102.short
4100  - http://jnm.snmjournals.org/content/57/7/1102.full
SO  - J Nucl Med2016 Jul 01; 57
AB  - The PET Response Criteria in Solid Tumors (PERCIST) are not specific regarding the number of lesions that should be analyzed per patient. This study evaluated how the number of analyzed lesions affects response assessment in metastatic breast cancer. Methods: In 60 patients, response was assessed by the change in SUVpeak, normalized to lean body mass, of the most 18F-FDG–avid lesion (PERCIST 1) and by the change in the sum of normalized SUVpeak for up to 5 lesions (PERCIST 5). The correlation between response by PERCIST and progression-free and disease-specific survival was evaluated. Results: In responders and nonresponders, the respective progression-free survival at 2 y was 37.26% and 6.43% for PERCIST 1 (P < 0.0001) and 33.65% and 7.14% for PERCIST 5 (P < 0.0001) and the respective disease-specific survival at 4 y was 58.96% and 25.44% for PERCIST 1 (P < 0.012) and 59.12% vs 20.01% for PERCIST 5 (P < 0.002). Conclusion: The number of analyzed lesions does not appear to have a major impact on the prognostic value of response assessment with 18F-FDG PET/CT in metastatic breast cancer.